Kiniksa Pharmaceuticals, Ltd. to Post FY2027 Earnings of $0.15 Per Share, Wedbush Forecasts (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities researchers at Wedbush cut their FY2027 earnings estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Tuesday, April 2nd. Wedbush analyst D. Nierengarten now expects that the company will earn $0.15 per share for the year, down from their previous estimate of $0.16. Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals' current full-year earnings is ($0.05) per share.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The business had revenue of $83.40 million for the quarter, compared to analysts' expectations of $72.31 million.

Separately, TheStreet raised Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Down 1.0 %

Shares of Kiniksa Pharmaceuticals stock traded down $0.18 on Thursday, hitting $18.06. The stock had a trading volume of 368,541 shares, compared to its average volume of 412,204. The stock's 50-day simple moving average is $19.71 and its two-hundred day simple moving average is $17.94. Kiniksa Pharmaceuticals has a one year low of $10.29 and a one year high of $22.09. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 100.34 and a beta of 0.27.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Swiss National Bank raised its holdings in shares of Kiniksa Pharmaceuticals by 13.8% during the 1st quarter. Swiss National Bank now owns 60,100 shares of the company's stock worth $597,000 after acquiring an additional 7,300 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Kiniksa Pharmaceuticals by 23.8% during the 1st quarter. JPMorgan Chase & Co. now owns 17,825 shares of the company's stock worth $177,000 after acquiring an additional 3,431 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Kiniksa Pharmaceuticals by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 137,001 shares of the company's stock worth $1,363,000 after acquiring an additional 3,095 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Kiniksa Pharmaceuticals by 0.3% during the 1st quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock worth $34,734,000 after acquiring an additional 10,473 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals by 126.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock worth $3,588,000 after acquiring an additional 201,622 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 12,742 shares of the business's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares in the company, valued at approximately $1,517,065.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Sanj K. Patel sold 5,582 shares of the business's stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $21.00, for a total value of $117,222.00. Following the transaction, the chief executive officer now directly owns 65,012 shares of the company's stock, valued at approximately $1,365,252. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The disclosure for this sale can be found here. Insiders sold a total of 33,109 shares of company stock worth $709,929 in the last three months. 54.23% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.